3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
95
Breast Neoplasms, Male
6
Advanced Breast Cancer
4
Triple Negative Breast Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Infertility
2
Sexual Dysfunctions, Psychological
1
Primary Ovarian Insufficiency
1
Patient Compliance
1
Osteitis Deformans
1
Inflammatory Breast Neoplasms
1
Hyperlipidemias
1
Hormone-sensitive Metastatic Breast Cancer
1
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Breast Diseases
1
Breast Cancer Invasive
1
Anatomic Stage I Breast Cancer AJCC v8
1
Advanced Metastatic Breast Cancer
1
Interventions
Fulvestrant
10
Letrozole
4
Alpelisib
4
ribociclib
3
palbociclib
3
Paclitaxel
2
NVP-BKM120
2
volagidemab
1
serabelisib
1
sapanisertib
1
olaparib
1
liposomal doxorubicin
1
gedatolisib
1
exemestane
1
dapagliflozin
1
capivasertib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Secretin
1
STX-478
1
Metformin
1
Lomustine
1
Leuprolide
1
Irinotecan
1
Imlunestrant
1
Goserelin
1
Gemcitabine
1
Drug Therapy
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Goserelin
×
Breast
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts